SciClone Pharmaceuticals on FORTUNE’s List of the 100 Fastest Growing Companies

September 24, 2012

FORTUNE Magazine has released its annual ranking of the 100 Fastest-Growing Companies in the country. SciClone is a specialty pharmaceutical company with a broad marketed product portfolio of differentiated therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders ranks #39.

To qualify, a company- domestic or foreign- must be trading on a major U.S. stock exchange; report data in U.S. dollars; file quarterly reports with the SEC; have a minimum market capitalization of $250 million and a stock price of at least $ 5 on June 29, 2012; and have been trading continuously since June 30, 2009. Companies must have revenue and net income of at least $50 million and $10 million, respectively, for the four quarters ended on or before April 30, 2012; and have posted an annualized growth in revenue and earnings per share of at least 20% annually over the three years ended on or before April 30, 2012.

Companies that meet these criteria are ranked by revenue growth rate; EPS growth rate; and three-year annualized total return for the period ended June 29, 2012. (To compute the revenue and EPS growth rates, Fortune uses a trailing four quarters log linear least square regression fit.)

The overall rank is based on the sum of the three ranks. Once the 100 companies are identified, they are then re-ranked within the 100, using the three equally weighted variables. If there is a tie, the company with the larger four-quarter revenue receives the higher rank.